文献速递淋巴瘤

伊布替尼治疗下调慢性淋巴细胞白血病中AID酶及增殖组分

Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.
PubMed 文献 · Blood · 2019-02-27

该研究分析慢性淋巴细胞白血病(CLL)队列在伊布替尼治疗前后的AID表达与增殖组分(PFs),发现伊布替尼降低PFs并减少AID表达,与AKT和Janus激酶1信号减弱相关;伊布替尼在CLL细胞系中增加AID表达,但在原代CLL样本中无此作用。

要点

  • 伊布替尼降低CLL增殖组分并减少AID表达,与AKT和Janus激酶1信号减弱相关。
  • 伊布替尼在CLL细胞系中增加AID表达,但在原代CLL样本中无此作用。
  • 结果提示伊布替尼与idelalisib在诱导AID方面可能不同。

核心结论

  • 伊布替尼降低CLL增殖组分并减少AID表达,与AKT和Janus激酶1信号减弱相关;伊布替尼在CLL细胞系中增加AID表达,但在原代CLL样本中无此作用。

研究设计与样本

  • 分析CLL队列在伊布替尼治疗前及治疗期间的AID表达和增殖组分。

主要发现

  • 伊布替尼降低CLL的增殖组分。
  • 伊布替尼减少AID表达,与AKT和Janus激酶1信号减弱相关。
  • 伊布替尼在CLL细胞系中增加AID表达,但在原代CLL样本中无此作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Activation-induced cytidine deaminase (AID) initiates somatic hypermutation and class switch recombination of the immunoglobulin genes. As a trade-off for its physiological function, AID also contributes to tumor development through its mutagenic activity. In chronic lymphocytic leukemia (CLL), AID is overexpressed in the proliferative fractions (PFs) of the malignant B lymphocytes, and its anomalous expression has been associated with a clinical poor outcome. Recent preclinical data suggested that ibrutinib and idelalisib, 2 clinically approved kinase inhibitors, increase AID expression and genomic instability in normal and neoplastic B cells. These results raise concerns about a potential mutagenic risk in patients receiving long-term therapy. To corroborate these findings in the clinical setting, we analyzed AID expression and PFs in a CLL cohort before and during ibrutinib treatment. We found that ibrutinib decreases the CLL PFs and, interestingly, also reduces AID expression, which correlates with dampened AKT and Janus Kinase 1 signaling. Moreover, although ibrutinib increases AID expression in a CLL cell line, it is unable to do so in primary CLL samples. Our results uncover a differential response to ibrutinib between cell lines and the CLL clone and imply that ibrutinib could differ from idelalisib in their potential to induce AID in treated patients. Possible reasons for the discrepancy between preclinical and clinical findings, and their effect on treatment safety, are discussed.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Morande PE, Sivina M, Uriepero A, et al. Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia. Blood. 2019. PMID: 30814061. doi:10.1182/blood-2018-09-876292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。